P - Contraindicated in pregnancy
L - Contraindicated in lactation
Flunarizine (brand name Sibelium) is a drug classified as a calcium channel blocker. Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. It may help to reduce the severity and duration of attacks of paralysis associated with the more serious form of alternating hemiplegia.
Flunarizine has H1-receptor blocking action and calcium-channel blocking effect. It has also been used as an adjunct epileptic therapy for patients refractory to standard treatment regimens.
Absorption
Absorbed well from the GI tract (oral).
Distribution
Highly lipophilic. Protein-binding: >90%.
Metabolism
Extensive.
Excretion
Via bile (as metabolites); 18 days (elimination half-life).
Information Not Available
Drowsiness. Rarely wt gain, headache, depression, gastric pain, dry mouth, insomnia, extrapyramidal reactions, galactorrhoea.
Information Not Available
Driving or operating machinery, epilepsy, elderly, CVS disease, glaucoma.
Plasma levels reduced by phenytoin, carbamazepine, valproic acid.
Information Not Available
Oral
Prophylaxis of migraine, Prophylaxis of vertigo and vestibular disorders, Prophylaxis of peripheral and cerebrovascular disorders
Adult: 5-10 mg daily at bedtime.
May be taken with or without food
Contraindicated in pregnancy
Contraindicated in lactation
Information Not Available
Information Not Available
Pregnancy, lactation, GI or urinary tract obstruction, acute porphyrias
Oral
Store below 25°C
Oral
Store below 25°C
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.